iSpecimen Inc. (NASDAQ:ISPC – Get Free Report) was the target of a significant growth in short interest in March. As of March 13th, there was short interest totaling 3,073,818 shares, a growth of 227.2% from the February 26th total of 939,560 shares. Approximately 35.8% of the company’s stock are short sold. Based on an average daily volume of 31,293,206 shares, the days-to-cover ratio is currently 0.1 days.
Institutional Trading of iSpecimen
A hedge fund recently bought a new stake in iSpecimen stock. Virtu Financial LLC purchased a new stake in shares of iSpecimen Inc. (NASDAQ:ISPC – Free Report) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 63,257 shares of the company’s stock, valued at approximately $82,000. Virtu Financial LLC owned approximately 0.65% of iSpecimen at the end of the most recent quarter. Hedge funds and other institutional investors own 13.62% of the company’s stock.
Analysts Set New Price Targets
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of iSpecimen in a report on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.
iSpecimen Stock Performance
iSpecimen stock opened at $0.16 on Friday. The stock has a market cap of $1.54 million, a PE ratio of -0.02 and a beta of 1.87. The stock has a 50-day moving average of $0.28 and a two-hundred day moving average of $0.58. iSpecimen has a one year low of $0.14 and a one year high of $3.18.
iSpecimen Company Profile
iSpecimen, Inc (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.
Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality.
Further Reading
Receive News & Ratings for iSpecimen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iSpecimen and related companies with MarketBeat.com's FREE daily email newsletter.
